JP2025507971A5 - - Google Patents
Info
- Publication number
- JP2025507971A5 JP2025507971A5 JP2024552478A JP2024552478A JP2025507971A5 JP 2025507971 A5 JP2025507971 A5 JP 2025507971A5 JP 2024552478 A JP2024552478 A JP 2024552478A JP 2024552478 A JP2024552478 A JP 2024552478A JP 2025507971 A5 JP2025507971 A5 JP 2025507971A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- independently
- optionally
- methyl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316595P | 2022-03-04 | 2022-03-04 | |
| US63/316,595 | 2022-03-04 | ||
| PCT/CA2023/050280 WO2023164775A1 (en) | 2022-03-04 | 2023-03-03 | Radiolabeled compounds targetng the prostate-specific membrane antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507971A JP2025507971A (ja) | 2025-03-21 |
| JP2025507971A5 true JP2025507971A5 (enExample) | 2026-03-10 |
Family
ID=87882764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552478A Pending JP2025507971A (ja) | 2022-03-04 | 2023-03-03 | 前立腺特異的膜抗原を標的とする放射性標識化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250186627A1 (enExample) |
| EP (1) | EP4486756A1 (enExample) |
| JP (1) | JP2025507971A (enExample) |
| AU (1) | AU2023226956A1 (enExample) |
| CA (1) | CA3244865A1 (enExample) |
| WO (1) | WO2023164775A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12472272B2 (en) | 2019-04-17 | 2025-11-18 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer |
| EP4590664A1 (en) * | 2023-09-12 | 2025-07-30 | Shanghai Sinotau Biotech. Co., Ltd | Inhibitors of prostate specific membrane antigen and use thereof |
| WO2025055942A1 (en) * | 2023-09-12 | 2025-03-20 | Shanghai Sinotau Biotech. Co., Ltd | Inhibitors of prostate specific membrane antigen and use thereof |
| WO2026002208A1 (zh) * | 2024-06-28 | 2026-01-02 | 思路迪生物医药(上海)有限公司 | 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11147889B2 (en) * | 2016-11-23 | 2021-10-19 | Cancer Targeted Technology Llc | Albumin-binding PSMA inhibitors |
| KR102843240B1 (ko) * | 2017-05-24 | 2025-08-05 | 이테엠 이소토페 테크놀로기에스 뮈니치 에스이 | 신규 psma-결합제 및 이의 용도 |
| CA3144094A1 (en) * | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| US11850291B2 (en) * | 2019-10-25 | 2023-12-26 | National Atomic Research Institute | PSMA targeted radiotherapy medicine and preparation method thereof |
-
2023
- 2023-03-03 EP EP23762646.0A patent/EP4486756A1/en active Pending
- 2023-03-03 JP JP2024552478A patent/JP2025507971A/ja active Pending
- 2023-03-03 WO PCT/CA2023/050280 patent/WO2023164775A1/en not_active Ceased
- 2023-03-03 US US18/842,681 patent/US20250186627A1/en active Pending
- 2023-03-03 CA CA3244865A patent/CA3244865A1/en active Pending
- 2023-03-03 AU AU2023226956A patent/AU2023226956A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5752315B2 (ja) | ４−（４−（３−（４−クロロ−３−（トリフルオロメチル）フェニル）ウレイド）−フェノキシ）−Ｎ−（１’，１’，１’−トリデューテロメチル）ピコリンアミドのｐ−トルエンスルホン酸塩（ＣＭ４３０７・ＴｓＯＨ）、ＣＭ４３０７・ＴｓＯＨの製造方法、及びＣＭ４３０７・ＴｓＯＨを含有する医薬組成物 | |
| JP2018516851A5 (enExample) | ||
| JP2022537773A5 (enExample) | ||
| TW200848078A (en) | Ligands for imaging cardiac innervation | |
| JP6164556B2 (ja) | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 | |
| CN102180780A (zh) | 茚酮类衍生物及其作为淀粉样蛋白沉积物和神经纤维缠结的显像剂和聚集抑制剂的用途 | |
| JP2010524965A (ja) | ジフェニル−ヘテロアリール誘導体並びにアミロイド斑への結合及び画像化のためのその使用 | |
| JP2023538524A5 (enExample) | ||
| JP2020531463A5 (enExample) | ||
| JP2007505044A5 (enExample) | ||
| JP2024502178A5 (enExample) | ||
| AU2017311510A1 (en) | Chelated PSMA inhibitors | |
| JP2025516719A5 (enExample) | ||
| TW201641492A (zh) | 經取代1,2,3-三唑、其用途、以及包含其之醫藥組成物 | |
| JP2834328B2 (ja) | 癌治療法 | |
| JP2005532269A5 (enExample) | ||
| JP2023524519A5 (enExample) | ||
| JPH01128962A (ja) | 抗新生物剤としてのポリアミン誘導体類 | |
| JPWO2019031614A5 (enExample) | ||
| CN110845408A (zh) | 同位素富集的乐伐替尼 | |
| RU2011101661A (ru) | Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний | |
| JP2011521947A5 (enExample) | ||
| JP2009534449A (ja) | １，４−ナフトキノン系化合物、該化合物を含んでなる組成物、およびこれらの化合物の抗がん剤としての使用 | |
| JP2015529660A (ja) | 新規な化合物およびその使用 | |
| JP2017071567A (ja) | 抗がん剤デリバリー分子 |